NEW

Home | Hindi original

Fake and Spurious Drugs: How Big Is the Risk, What the Law Says

News context: 18 November 2026 | Prelims: GS-2 (health and regulation) | Mains: GS-2, GS-3

In this article: News context, spurious vs NSQ vs counterfeit, National Drug Survey data, law and regulators, practice questions, FAQ

Fake and Spurious Drugs: How Big Is the Risk, What the Law Says
Original symbolic illustration: pcsmantra.com

Why in the news

Reports of a raid on a licensed distributor in Karnataka, allegedly seizing fake cancer drugs, have alarmed patients. The state government is yet to officially confirm that the seized medicines were indeed counterfeit cancer drugs, and a list circulating on social media mentioned only antibiotics. Meanwhile, on 18 November, drug department teams raided 40 locations in Bihar including Patna and found an illegal factory, while a fake-medicine racket was also busted in Moradabad, Uttar Pradesh. Earlier this month, the Centre proposed instant suspension of manufacturing licences for drugs that fail quality tests. Together these developments have reopened the debate on fake drugs, their real scale and the regulatory system.

Spurious, NSQ and counterfeit: the difference

For exam purposes the three terms are distinct:

The World Health Organization uses the umbrella term "Substandard and Falsified (SF) medical products".

What the data says: the National Drug Survey

The most cited figures on fake drugs in India come from a national survey published in 2017, commissioned by the Health Ministry and carried out by the National Institute of Biologicals (NIB), Noida, over 2014-16:

The takeaway: while public debate focuses on "fake drugs", the data shows India's real challenge is substandard quality, especially in the government supply chain.

Law and regulators

Challenges and way forward

Prelims Practice Questions

Question 1

With reference to drug regulation in India, consider the following statements:

Statement 1: Section 17-B of the Drugs and Cosmetics Act, 1940 defines spurious drugs
Statement 2: The Central Drugs Standard Control Organisation is headed by the Drugs Controller General of India
Statement 3: The national survey published in 2017 estimated the share of spurious drugs in India at about 10%

Which of the statements given above are correct?

Answer and Explanation

Correct answer: (a)

Statement 1: Correct - Section 17-B defines spurious drugs
Statement 2: Correct - CDSCO is headed by the DCGI
Statement 3: Incorrect - spurious drugs were estimated at 0.0245%; the 10.02% figure refers to NSQ drugs in the government supply chain

Question 2

With reference to the National Drug Survey (2014-16) published in 2017, consider the following statements:

Statement 1: It was entrusted by the Health Ministry to the National Institute of Biologicals, Noida
Statement 2: It found the share of substandard (NSQ) drugs in the government supply chain to be higher than in the retail market
Statement 3: The survey was limited to samples from metropolitan cities

Which of the statements given above are correct?

Answer and Explanation

Correct answer: (a)

Statement 1: Correct - NIB Noida conducted it for the Health Ministry
Statement 2: Correct - 10.02% NSQ in the government chain versus 3% in retail
Statement 3: Incorrect - samples covered 654 districts in 36 States and UTs

Frequently Asked Questions (FAQ)

What is the difference between a spurious and an NSQ drug?

A spurious drug is a deliberate fake (Section 17-B), while an NSQ drug is genuine but fails laboratory quality standards.

Who regulates drugs in India?

The CDSCO (headed by the DCGI) at the Centre and State drug control authorities in the States, under the Drugs and Cosmetics Act, 1940.

What proposal on drug quality came in November 2026?

Instant suspension of manufacturing licences for drugs failing quality tests.

Sources

Download this article: PDF